[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356267-105":59,"doc-detail-356267-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","low-dose-simvastatin-protects-pancreatic-cancer-cells-by-promoting-mitochondrial-autophagy-through-tfeb","Low-dose Simvastatin protects pancreatic cancer cells by promoting mitochondrial autophagy through TFEB","","Pancreatic cancer forms dense fibrotic stroma and exhibits abnormal, irregular vasculature that limits drug penetration and delivery to tumor core cells. Statins, initially developed for cardiovascular prevention, show emerging anticancer potential, yet clinical findings are inconsistent and dose-dependent, likely due to the tumor’s constrained blood supply and fibrosis. This study examines how low-dose simvastatin affects pancreatic cancer cells and uncovers underlying mechanisms involving mitochondrial autophagy and TFEB-mediated pathways.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/low-dose-simvastatin-protects-pancreatic-cancer-cells-by-promoting-mitochondrial-autophagy-through-tfeb/356267/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/low-dose-simvastatin-protects-pancreatic-cancer-cells-by-promoting-mitochondrial-autophagy-through-tfeb/356267.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is simvastatin more effective at low doses against pancreatic cancer cells?","Question",{"text":112,"@type":113},"The dense fibrosis and insufficient, irregular blood supply in pancreatic tumors restrict drug delivery. The study concludes that simvastatin exerts its effects on pancreatic cancer cells mainly at low doses under these constraints.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What mechanisms does low-dose simvastatin promote in pancreatic cancer cells?",{"text":117,"@type":113},"Low-dose simvastatin increases mitophagy. It produces more mitophagosomes, enhances lysosome–mitochondria co-localization, and promotes TFEB nuclear translocation.",{"name":119,"@type":110,"acceptedAnswer":120},"How was TFEB’s role linked to downstream targets in this study?",{"text":121,"@type":113},"Chromatin immunoprecipitation and dual-luciferase reporter assays confirmed TFEB as the transcription factor for P62/SQSTM1, connecting TFEB nuclear translocation to mitophagy induction.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356267,1790219105,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Cellular Oncology (2026) 49:28  \n[https://doi.org/10.1007/s13402-026-01](https://doi.org/10.1007/s13402-026-01)164-y  \nRESEARCH  \nLow-dose Simvastatin protects pancreatic cancer cells by promoting mitochondrial autophagy throughTFEB  \nZhiliang Wang1 · Di Wu1 · Yue Zhang1 · Weibo Chen1 · Shupei Fan1 · Yang Yang1 · Yue Yang1 · Guangchen Zu1 · Yong An1 · Yuchi Jin6 · Aining Kang6 · Yanxun Zou6 · Yi Liu6 · Xianjun Yu2,3,4,5 · Yi Qin2,3,4,5 · Xiaowu Xu2,3,4,5 · Xuemin Chen1  \nReceived: 19 September 2025 / Accepted: 7 January 2026 © The Author(s) 2026  \nAbstract  \nBackground Pancreatic cancer is typically accompanied by fibrosis, forming a dense stromal matrix. This dense matrix restricts drug penetration, making it difficult for drugs to effectively reach tumor cells. Additionally, pancreatic cancer has inadequate local blood supply and “vascular irregularity,” which makes it challenging for drugs to reach the core of the tumor. Even if some drugs reach the pancreas through systemic circulation, poor vascular permeability prevents them from effectively entering tumor cells, resulting in suboptimal therapeutic effects. Statins were initially used to treat high cholesterol levels and prevent cardiovascular diseases, but recent studies suggest that they may also have potential therapeutic effects on cancer, particularly certain types of cancer such as pancreatic cancer. However, clinical research on the use of statins for pancreatic cancer treatment is still ongoing, and the results are inconsistent. The effects of statins on pancreatic cancer may vary depending on the dose. Due to the aforementioned limitations of fibrosis and lack of blood supply in pancreatic cancer, simvastatin only exerts its effect on pancreatic cancer cells at low doses.  \nPurpose This study aimed to explore the effects of low-dose simvastatin on pancreatic cancer cells and the underlying mechanisms. We investigated the effects of different concentrations of simvastatin on pancreatic cancer cells.  \nMethods The vitality of the cells was evaluated by CCK8, EDU staining, and the level of ferroptosis in pancreatic cancer cells was detected by flow cytometry detection ofC11, MDA, ROS.  \nResults We found that small doses of simvastatin can resist the toxicity of Erastin against pancreatic cancer cells. Under the transmission electron microscope, more mitophagosomes were produced in pancreatic cancer cells treated with small dose of simvastatin, and immunofluorescence revealed increased co-localization of lysosomes and mitochondria, indicating that simvastatin promoted the occurrence of mitophagy. At the same time, immunofluorescence confirmed that simvastatin promoted the nuclear translocation ofTFEB, and chromatin immunoprecipitation and dual-luciferase gene report confirmed that TFEB is the transcription factor of P62/SQSTM1 . This study clarified that a small dose of simvastatin, in the event of mitochondrial stress in pancreatic cancer cells, induces mitophagy to clear damaged mitochondria, protecting pancreatic cancer cells from ferroptosis and apoptosis, by promoting the transcription of P62/SQSTM1 through the nuclear translocation ofTFEB.  \nConclusion These findings may explain one of the reasons for the suboptimal efficacy of simvastatin in the treatment of pancreatic cancer, while also providing new insights for research on the antitumor effects of statins.  \nKeywords TFEB · Simvastatin · P62 · Mitochondrial autophagy  \nZhiliang Wang, Di Wu and Yue Zhang contributed equally to this work.  \nExtended author information available on the last page of the article  \n1 3  \n1 Introduction  \nThe incidence and mortality rates of pancreatic cancer have been steadily increasing globally, particularly in developed countries. According to the latest statistics, pancreatic cancer is the fourth leading cause of cancer-related death in the United States, and it is expected to become the second leading cause by 2030 [1].The five-year survival rate for pancreatic cancer is ve","cbCaiuk738zr3c9m","https://ap.wps.com/l/cbCaiuk738zr3c9m","pdf",15149980,"English","# Abstract\n## Background\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"Why is simvastatin more effective at low doses against pancreatic cancer cells?\",\"answer\":\"The dense fibrosis and insufficient, irregular blood supply in pancreatic tumors restrict drug delivery. The study concludes that simvastatin exerts its effects on pancreatic cancer cells mainly at low doses under these constraints.\"},{\"question\":\"What mechanisms does low-dose simvastatin promote in pancreatic cancer cells?\",\"answer\":\"Low-dose simvastatin increases mitophagy. It produces more mitophagosomes, enhances lysosome–mitochondria co-localization, and promotes TFEB nuclear translocation.\"},{\"question\":\"How was TFEB’s role linked to downstream targets in this study?\",\"answer\":\"Chromatin immunoprecipitation and dual-luciferase reporter assays confirmed TFEB as the transcription factor for P62/SQSTM1, connecting TFEB nuclear translocation to mitophagy induction.\"}]","Low-dose Simvastatin protects pancreatic cancer cells by promoting mitochondrial autophagy through TFEB | PDF",1790124356,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dc3c19ddb870c92af67d2bcf96d26c1.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/183bb709ec7f81a8f3e55065bfcf37cd.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c3a1deac5cf425f3e8d01f2f7f914ad.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a204f843e1b745b22d3d81afa94477cd.webp",980,1301]